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Abstract
 
Structural studies have shown that class I major histocompatibility complex (MHC)-restricted
 
peptide-specific T cell receptor (TCR)-
 
a
 
/
 
b
 
s make multiple contacts with the 
 
a
 
1 and 
 
a
 
2 heli-
ces of the MHC, but it is unclear which or how many of these interactions contribute to func-
tional binding. We have addressed this question by performing single amino acid mutagenesis
of the 15 TCR contact sites on the human histocompatibility leukocyte antigen (HLA)-A2
molecule recognized by the A6 TCR specific for the Tax peptide presented by HLA-A2. The
results demonstrate that mutagenesis of only three amino acids (R65, K66, and A69) that are
clustered on the 
 
a
 
1 helix affected T cell recognition of the Tax/HLA-A2 complex. At least
one of these three mutants affected T cell recognition by every member of a large panel of
 
Tax/HLA-A2–specific T cell lines. Biacore measurements showed that these
 
 
 
three HLA-A2
mutations also altered A6 TCR binding kinetics, reducing binding affinity. These results show
that for Tax/HLA-A2–specific TCRs, there is a location on the central portion of the 
 
a
 
1 helix
that provides interactions crucial to their function with the MHC molecule.
Key words: T cell receptor • major histocompatibility complex class I–peptide complex • 
 
T cell activation • CD8
 
1
 
 T cell • binding kinetics
 
Introduction
 
The TCR-
 
a
 
/
 
b
 
 determines the specificity of T cell re-
sponses. This specificity is for regions of the MHC mole-
cule as well as for the peptide bound in the peptide binding
groove of the MHC molecule. Structural studies have
shown that the TCR binds to the MHC/peptide complex
in a diagonal mode that permits the interaction of CDR
loops with both the peptide and the MHC molecule (1–8).
For T cells that recognize class I MHC/peptide complexes,
amino acids that compose the variable regions of the 
 
a
 
 and
 
b
 
 chains of the TCR make multiple contacts with both the
 
a
 
1 and 
 
a
 
2 helices of the MHC (1–7).
The first structure of a human TCR-
 
a
 
/
 
b
 
/peptide/
MHC complex to be determined was the A6 TCR specific
for the human T lymphotropic virus type I Tax peptide
(LLFGYPVYV) presented by HLA-A2 (2). The A6 TCR
 
buries a total of 1,031 Å
 
2
 
 of solvent accessible surface area
of the Tax/HLA-A2 complex (2). Of this total buried sur-
face area, 695 Å
 
2
 
 or 67% of that area is HLA-A2 alone. 15
amino acids on HLA-A2 are contacted by the A6 TCR, 6
on the 
 
a
 
1, and 9 on the 
 
a
 
2 helices. Although the high res-
olution structure of the A6 TCR/Tax peptide/HLA-A2
complex provides a clear picture of the interface between
these proteins, it does not provide direct information about
the contributions of the various TCR-peptide/MHC con-
tacts. Conceptually, there are two possibilities: (a) the bind-
ing free energy
 
 
 
between the two proteins could be gener-
ated by only a few strong interactions; or (b) accumulation
of many weaker contacts over the entire interface could
provide the necessary binding energy. It is currently un-
known whether one or both of these possibilities applies.
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Many studies have examined the effects of MHC mutations
on TCR recognition (e.g., 9–11), but none of these MHC
mutant studies have had the advantage of
 
 
 
being able to
 
 
 
pre-
cisely target and isolate the TCR contact residues identified
by a high resolution structure of the trimolecular complex.
In this study, we have used the knowledge of the TCR
contacts between the A6 TCR and HLA-A2 (2) to per-
form alanine scanning mutagenesis of the HLA-A2 contact
residues to determine whether a few key residues provided
most of the required interactions, or whether there were
many amino acids on both helices provided these interac-
tions. The rationale for performing alanine substitutions is
that this protocol deletes all interactions made by atoms be-
yond the 
 
b
 
 carbon and provides an estimate of the contri-
bution to binding energy made by the missing portion of
the side chain (12). The mutant HLA-A2 molecules with
substitutions in each of these 15 TCR contacts were then
compared with wild-type HLA-A2 molecules for their ca-
pacity to present the Tax peptide to A6 TCR-bearing
clones. The affinity of soluble A6 TCR for soluble wild-
type and mutant HLA-A2/Tax complexes was measured
by Biacore (surface plasmon resonance) to more precisely
quantitate the effects of the mutations on TCR binding.
 
Materials and Methods
 
Generation and Expression of HLA-A2 Mutant Transfectants.
 
The full-length HLA-A
 
*
 
0201 cDNA construct RSV/HLA-A2
(13) was used as a template for mutagenesis by the method of Ho
et al. (14). The full-length template was obtained by PCR using
the following primers: 5
 
9
 
-TGGGCTGCAGGTCGACTCTA-
GAGGAT-3
 
9
 
 and 5
 
9
 
-GCCCGGATCCTCTCAGTCCCTCA-
CAAGGCAGC-3
 
9
 
 obtained from Genset. The PCR product
was treated with SalI and BamHI (sites underlined), purified, and
ligated into the RSV.5neo mammalian expression plasmid (15).
Automated DNA sequencing was performed at this stage to con-
firm the results of mutagenesis by the National Institute of Neu-
rological Disorders and Stroke DNA Sequencing Facility.
HMy2.C1R cells (16) were transfected with full-length RSV/
HLA-A2 constructs by Lipofectin (Life Technologies). Clones
were assayed for surface expression using the anti–HLA-A2 anti-
bodies BB7.2 and MA2.1 (17–20) with a FACSCalibur™ (Bec-
ton Dickinson).
 
Production and Isolation of Soluble Mutant HLA-A2 Heavy
Chains.
 
A soluble form of the HLA-A2 heavy chain was pro-
duced by the pHN1
 
1
 
/HLA-A201 cDNA construct that encodes
amino acids 1–275 of the heavy chain (21). Mutagenesis was per-
formed as described above for the full-length constructs, and the
PCR product was generated using the following primers: 5
 
9
 
-
ACACAGGAAACAGAATTCAGGAGGAAT-3
 
9
 
 and 5
 
9
 
-GCC-
AAAACAGAAGCTTTCACTCCCATCT-3
 
9
 
. The PCR prod-
uct was treated with EcoRI and HindIII (sites underlined), puri-
fied, and ligated into the pHN1
 
1
 
 bacterial expression plasmid
(22). XL-1 Blue competent bacteria (Stratagene) were trans-
formed with HLA-A2/pHN1
 
1
 
 constructs, and colonies were se-
lected and DNA isolated; the presence of constructs was con-
firmed by restriction enzyme analysis, and DNA sequencing
performed as described above. Positive clones were grown in 6 li-
ter volumes and inclusion bodies containing the soluble HLA
heavy chains were isolated (23). The presence of HLA heavy
chains was confirmed by SDS/PAGE.
 
Generation of Soluble HLA-A2/
 
b
 
2m/Tax Peptide and A6 TCR-
 
a
 
/
 
b
 
 Complexes.
 
Soluble forms of the HLA-A2/Tax peptide
complexes and the A6 TCR-
 
a
 
/
 
b 
 
were refolded from purified in-
clusion bodies as described
 
 
 
(21, 23). In brief, for HLA-A2/Tax,
HLA-A2 heavy chain and 
 
b
 
2m inclusion bodies were rapidly di-
luted into a refolding solution (final concentrations 1 
 
m
 
M heavy
chain and 2 
 
m
 
M 
 
b
 
2m) containing an excess (30 
 
m
 
M) Tax pep-
tide. For the A6 TCR, 
 
a
 
 and 
 
b
 
 chain inclusion bodies were rap-
idly diluted into refolding buffer (final concentrations of 2 
 
m
 
M).
After incubation at 4
 
8
 
C for 
 
z
 
24 h, refolded protein was concen-
trated and purified via size-exclusion chromatography. The A6
TCR construct used contains the 
 
a
 
 and 
 
b
 
 chains up to, and in-
cluding, the cysteines encoding the interchain disulfide bond, fol-
lowed by a heterodimeric coiled-coil (24) to stabilize the 
 
ab
 
dimer during refolding and analysis. A single free cysteine was
added to the COOH terminus of the 
 
b
 
 chain construct for cou-
pling to a Biacore chip (5).
 
Biacore Measurements.
 
Biacore measurements were per-
formed on Biacore 1000 and 2000 instruments (Biacore, Inc.) as
described previously (5). In brief, the TCR was attached to a
CM5 sensor chip using the free cysteine engineered at the
COOH terminus of the 
 
b
 
 chain using thiol coupling. Steady-
state equilibrium experiments were performed by injecting 70 
 
m
 
l
of HLA-A2/Tax at a flow rate of 10 
 
m
 
l/min. The response was
determined by averaging the signal over the final 15 s of the in-
jection and subtracting the response from an identical injection
over a mock cysteine-coupled flowcell. Equilibrium response
versus injected concentration data were fit to a 1:1 binding
model. For kinetic experiments, 60 
 
m
 
l of MHC/peptide was in-
jected at a flow rate of 100 
 
m
 
l/min. Identical injections over the
mock flowcell were subtracted from the data. The entire associa-
tion and dissociation phases were fit to a 1:1 binding model ex-
cluding 
 
z
 
2 s at the beginning of each phase. As with our previ-
ous studies, we included a term for a small baseline drift during
fitting (5). Inclusion of this term, which typically amounted to
1–3% of the total binding response, improved the pattern of the
residuals, but had only a minor effect on the fitted parameters.
Solution conditions for all experiments were 10 mM Hepes, 150
mM NaCl, 3 mM EDTA, 0.005% polysorbate-20, pH 7.4, 25
 
8
 
C.
All injections were repeated twice. Analysis was performed using
Biavaluation 3.0 (Biacore, Inc.). For the equilibrium experiments,
errors in Table II
 
 
 
are the standard fitting error. Errors in kinetic
constants are standard deviations from multiple determinations.
Errors in 
 
k
 
off/
 
/
 
k
 
on
 
 and 
 
t
 
1/2
 
 values are derived from the errors in 
 
k
 
on
 
and 
 
k
 
off
 
 using statistical error propagation. HLA-A2/Tax concen-
trations were determined using an extinction coefficient of
95,839 M
 
2
 
1
 
cm
 
2
 
1
 
 (5); this coefficient was reduced by 5,500 for
the mutant W167A (25). Concentrations used were the average
of three independent dilutions.
 
T Cell Assays.
 
A6-TCR CD8
 
1
 
 T cell clones 2G4 and RS56
(26) and the B7-TCR T cell clone 10B7 (4) are specific for
HTLV-I Tax 11-19 (LLFGYPVYV) presented by HLA-A2. Ad-
ditional Tax-specific CTL lines were generated from the CD8
 
1
 
PBL of five additional HLA-A2
 
1
 
 HAM/TSP patients as de-
scribed previously (26). T cell lines specific for influenza virus
matrix peptide M1 58–66 (GILGFVFTL) presented by HLA-A2
(27) were generated from CD8
 
1
 
 PBLs of normal HLA-A2
 
1
 
 do-
nors as described (28). HLA-A2 allospecific CD8
 
1
 
 CTL lines
were selected by limiting dilution from a mixed lymphocyte cul-
ture of responder PBLs (HLA-A1, HLA-A3, HLA-B14, and
HLA-B44) and irradiated stimulator PBLs (HLA-A1, HLA-
A201, HLA-B44, and HLA-B55) as described previously (29).
Cytotoxicity assays and quantitation of secretion of IFN-
 
g
 
 and 
553
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macrophage inflammatory protein (MIP)
 
1
 
-1
 
b 
 
were performed as
described (4). Antigen-presenting cells were HLA-A2 or HLA-
A3 transfected Hmy2.C1R cells (16). Tyrosine phosphorylation
of TCR-associated 
 
z
 
-chains and ZAP-70 was quantitated by im-
munoprecipitation with a polyclonal rabbit anti–ZAP-70 (sup-
plied by Dr. L. Samelson, National Institutes of Health, Bethesda,
MD) and immunoblotting with the antiphosphotyrosine anti-
body 4G10 (Upstate Biotechnology), as described previously (4).
 
Circular Dichroism Temperature Melts.
 
The thermal stability of
peptide/MHC complexes was monitored by circular dichroism
(CD) spectroscopy (30, 31) using a Jasco J-710 instrument
equipped with a Peltier temperature regulator. Solution condi-
tions were 10 mM sodium phosphate, 10 mM NaCl, pH 7.4.
Protein concentrations were 
 
z
 
0.15 mg/ml. Denaturation was
monitored at the minimum of 218 nm between 25 and 90
 
8
 
C us-
ing a gradient of 1
 
8
 
C/min. Rather than constraining the data to a
two-state unfolding model, the data in the transition region were
fit to a 9-order polynomial equation and the apparent melting
temperature (
 
T
 
m
 
) determined from the maximum of the first de-
rivative of the fitted curve. The reported 
 
T
 
m
 
 values and associated
error are averages and standard deviations from three repeated
measurements with fresh samples.
 
Results
 
Mutation of A6 TCR Contacts with HLA-A2.
 
The crys-
tallographic structure of the trimolecular complex of the A6
TCR-
 
a
 
/
 
b
 
 bound to HTLV-I Tax 11–19 peptide/HLA-A2
revealed that this TCR contacted 15 amino acids on the
HLA-A2 molecule (reference 2; Fig. 1, and Table I; con-
tacts tabulated with a 4Å distance cutoff). Six of these
amino acids were on the 
 
a
 
1 helix of HLA-A2 (E58, R65,
K66, K68, A69, and Q72), and the remaining nine were on
the 
 
a
 
2 helix (Table I). Nine of the HLA-A2 amino acids
contacted by the A6 TCR were conserved among HLA
class I alleles, and six were variable (32; Table I). To exam-
ine the functional contributions of these amino acids, and to
 
1
 
Abbreviations used in this paper: 
 
CD, circular dichroism; MIP, macrophage
inflammatory protein.
Figure 1. Mutated HLA-A2 amino acids
mapped on the surface of the molecule.
Coloring indicates the effects of each muta-
tion upon function. Blue, no effect; red,
strong effect; yellow, intermediate effect.
See Table I for details. Image generated
with InsightII (MSI Inc.).
Table I. Summary of A6 TCR Interactions with HLA-A2
HLA-A2 residue
(conserved vs.
variable)
HLA-A2 residue
contacted by
A6 TCR
Mutant
HLA-A2
produced
Negative effect
on
Tax presentation*
Conserved E58 E58A 2
Variable R65 R65A 11
Variable K66 K66A 11
Conserved K68 K68A 2
Variable A69 A69G 1
Conserved Q72 Q72A 2
Conserved A149 A149G 2
Conserved A150 A150G 2
Variable H151 H151A 2
Conserved Q155 Q155A 2
Conserved A158 A158G 2
Variable T163 T163A 2
Conserved E166 E166A 2
Variable W167 W167A 2
Conserved R170 R170A 2
*Negative effects of mutant HLA-A2 molecules are scored as “2” if
they produced a ,10-fold reduction in the amount of Tax peptide
required to produce 50% of maximum lysis, IFN-g, and MIP-1b se-
cretion relative to wild-type HLA-A2, “1” if they produced a 10–100-
fold reduction in activity, and “11” if they produced a .100-fold
reduction in activity.554 Footprint on HLA-A2 for Tax Peptide/HLA-A2 TCR Recognition
determine if one particular area was critical for recognition
of the A6 TCR, site-directed mutagenesis was performed
on the HLA-A2 cDNA that substituted alanine for each of
these amino acid contacts (for cases in which alanine was
the contact residue, glycine was substituted for alanine).
Substitution by alanine (or glycine) deletes interactions
made by atoms beyond the b carbon and provides an esti-
mate of the contribution to binding energy made by the
original side chain (12). Wild-type and mutant HLA-A2
cDNAs were generated that encoded the full-length mole-
cule for transfection into Hmy2.C1R cells (16) and a trun-
cated soluble form for utilization in TCR binding assays
(21). Cell surface expression of the mutant HLA-A2 mole-
cules was quantitated by cytofluorometry using two differ-
ent HLA-A2 monoclonal antibodies that are known to re-
act against different HLA-A2 epitopes (BB7.2 and MA2.1;
references 17–20; Fig. 2). Only one of the HLA-A2 mutant
transfectants had less than a twofold level of expression rel-
ative to wild-type with both of these antibodies (W167A;
Fig. 2). Two of the mutants showed decreased reactivity
with MA2.1 but not BB7.2 (R65A and R170A; Fig. 2).
These results were consistent with previously published
findings on the specificity of MA2.1 (17, 19, 20).
A6 TCR-bearing Clonal T Cell Activation by HLA-A2
Contact Mutants. The effects of the HLA-A2 amino acid
substitutions on T cell activation were assessed by the ca-
pacity of the mutants to present the Tax peptide to the A6
TCR-bearing clones 2G4 and RS56. Activation was mea-
sured by a series of T cell effector assays: (a) cytotoxicity of
peptide-pulsed target cells; (b) induction of MIP-1b and
IFN-g secretion; and (c) phosphorylation of the TCR-asso-
ciated  z-chains and ZAP-70. Representative results are
presented in Fig. 3. The only dramatic negative effects pro-
duced were the alanine substitutions of R65 and K66,
which produced a .1,000-fold reduction in all three T cell
effector assays (Fig. 3, A–C), whereas the substitution of A69
with glycine produced a 10–100-fold decrease in the re-
Figure 2. Levels of cell surface expression of wild-type and mutant
HLA-A2 molecules. Hmy2.C1R cells were transfected with the indicated
mutant HLA-A2 constructs and levels of cell surface expression measured
by cytofluorometry using two different anti-A2 antibodies MA2.1 (top)
and BB7.2 (bottom). Untransfected cells served as a negative control
(Hmy). Y-axes are mean fluorescence intensity (M.F.I.).
Figure 3. Presentation of the Tax
peptide by wild-type and mutant HLA-
A2–transfected cells to A6 TCR-bear-
ing clones. Clone 2G4 was assayed for
the capacity to recognize Tax peptide-
pulsed antigen-presenting cells by (A)
direct lysis (E/T 6 2.5:1), (B) MIP-1b
secretion, and (C) IFN-g secretion. (D)
A6 TCR-mediated signal transduction
was quantitated by phosphorylation of
the p38 form of phospho-z-chains and
phosphorylation of ZAP-70 from clone
RS56 stimulated with the indicated un-
pulsed (2) or Tax peptide-pulsed anti-
gen-presenting cells. In A, additional ti-
trations of 0.01 and 0.001 mM peptide
for Tax, H151A, and T163A were in-
distinguishable, but were not shown be-
cause of x-axis compression.555 Baker et al.
sponses to the Tax peptide (Fig. 3, A and B). All of the
other mutants produced less than a 10-fold reduction in the
reactivity to the Tax peptide for each of these three assays
of T cell activation (Fig. 3, summarized in Table I).
If the negative effects on T cell effector functions pro-
duced by the R65A, K66A, and A69G mutations were due
to direct effects on TCR binding and signaling, then they
should produce changes in the most membrane proximal
TCR signaling events of phosphorylation of the TCR-asso-
ciated z-chains and ZAP-70 (33, 34). A6 TCR engage-
ment by wild-type HLA-A2 presentation of the Tax pep-
tide induces the characteristic agonist pattern of p38-z and
ZAP-70 phosphorylation (Fig. 3 D). Activation by R65A
and K66A presentation of the Tax peptide showed no de-
tectable phosphorylation of p38-z or ZAP-70 (Fig. 3 D).
The A69G mutant that had less of a negative effect on T
cell effector function showed a different partial agonist pat-
tern of phosphorylation, with some detectable p38-z phos-
phorylation, but no detectable ZAP-70 phosphorylation
(Fig. 3 D). A representative mutant that showed no nega-
tive effect on T cell effector functions (H151A) showed a
phosphorylation pattern indistinguishable from wild-type
HLA-A2 (Fig. 3 D). These results demonstrate that the
R65A, K66A, and A69G mutations selectively interfere
with A6 TCR recognition and signal transduction induced
by Tax/HLA-A2.
Effects of HLA-A2 Mutations on A6 TCR Binding of Solu-
ble Tax/HLA-A2 Complexes. The effects of several of the
amino acid substitutions on the kinetics and thermodynam-
ics of the A6 TCR to binding Tax/HLA-A2 complexes
were measured using Biacore. The three mutants that dem-
onstrated negative effects on TCR signaling (R65A, K66A,
and A69G) were examined, as were three that showed no
significant functional effects (T163A, E166A, and W167A).
Experiments were performed with the TCR covalently
coupled to the sensor chip through an engineered cysteine
at the COOH terminus of the b-chain. Both steady-state
equilibrium and kinetic Biacore experiments were per-
formed; in each, affinities resulting from the two measure-
ments were similar.
Representative Biacore data are shown in Fig. 4 A; all
binding data are summarized in Table II. With one excep-
tion, the substitutions resulted in moderate effects on KD,
values ranged from 12.4 mM (A69G) to 2.8 mM (T163A;
wild-type HLA-A2/Tax binds the A6 TCR with a KD of
0.82 mM; reference 5). The single mutation that had a large
effect on the KD was R65A, with a value of 96 mM, z120-
fold weaker than the wild-type.
The mutations resulted in large effects on binding kinet-
ics, with t1/2 ranging from 1.0 (A69G) to 13.9 s (K66A; t1/2
for the wild-type interaction is 7.5 s; reference 5). The
slow dissociation rates for the K66A and R65A mutants are
qualitatively apparent in Fig. 4 B. Each substitution also re-
sulted in an apparent decrease in association rate (kon) rela-
tive to the wild-type interaction (kon with wild-type HLA-
A2 is 1.1 3 105 M21s21; reference 5). The reductions in
kon for the R65A and K66A substitutions are substantial,
the respective values of 829 M21s21 and 3.2 3 103 M21s21
represent z133- and z34-fold decreases relative to wild-
type.
Effects of R65A, K66A, and A69G Mutations on Other
Tax/HLA-A2–specific T Cells. To determine if the nega-
tive effects of the R65A, K66A, and A69G mutations on
recognition of the Tax/HLA-A2 complex by the A6 TCR
are generalizable to other Tax/HLA-A2–specific T cells,
we assessed the reactivity of the B7 TCR, a second Tax/
HLA-A2–specific TCR-a/b, with each of the three mu-
tants. In the crystallographic structure of the B7 TCR
complexed with Tax/HLA-A2, Arg65, Lys66, and Ala69
form contacts with this TCR that are very similar to the
contacts these amino acids make with the A6 TCR (4).
Figure 4. Representative Biacore binding data. (A) Full kinetic dataset
for the Tax/HLA-A2 E166A mutant binding immobilized A6 TCR.
Red lines represent fits to a 1:1 binding model; injected concentrations
are indicated. Residuals are indicated below the data. Inset: separate equi-
librium binding experiment for E166A. (B) Representative kinetic traces
for wild-type Tax/HLA-A2, the K66A mutant, and the R65A mutant
binding to the A6 TCR. The slow dissociation rates for K66A and R65A
are apparent. Data are plotted as every fourth data point along with fits to
1:1 binding models. Plots represent one trace from full datasets as in A.
Injected TCR concentrations are indicated. RU, reasonable units.556 Footprint on HLA-A2 for Tax Peptide/HLA-A2 TCR Recognition
Reactivity of each of the mutants with the B7 TCR was
assayed by measuring the ability of the B7 TCR-expressing
T cell line 10B7 to lyse peptide-pulsed targets. As shown in
Fig. 5, the R65A and K66A mutants had a substantial loss
of activity with the B7 TCR that resembles the activity loss
with the A6 TCR. In contrast, the A69G mutant did not
have a significant effect with the B7 TCR.
To further address the general nature of the negative ef-
fects of the R65A, K66A, and A69G mutations on Tax/
HLA-A2–specific T cells, we next generated Tax/HLA-
A2–specific T cell lines from five additional HLA-A21
HAM/TSP patients and assayed them for the ability to lyse
Tax peptide-pulsed wild-type and mutant HLA-A2 target
cells. The results, summarized in Table III, show that of
201 Tax/HLA-A2–specific CTL lines assayed, at least one
of these three HLA-A2 mutants produced a negative effect
on Tax presentation on all of these CTL lines. Each of the
mutants showed no effect on Tax presentation by at least
four CTL lines, indicating that none of these three mutants
had an intrinsic negative effect on Tax presentation or the
ability to bind the Tax peptide. Taken together, these re-
sults indicate that the area on the a1 helix of the HLA-A2
molecule encompassing residues R65, K66, and A69 has an
important role in recognition of the HLA-A2 molecule by
Tax-specific TCRs.
Effects of R65A, K66A, and A69G Mutations on Other,
Non-Tax–specific, HLA-A2–restricted/specific T Cells. To
determine if all TCRs that recognize HLA-A2 focus on the
same a1 helical region (around amino acids R65, K66, and
A69), we tested T cell lines specific for influenza virus M1
58–66 presented by HLA-A2 (27) and HLA-A2–specific
alloreactive T cell lines derived from a mixed lymphocyte
culture reaction (29). 4 of 12 M1 58–66–specific T cell
lines and 4 of 11 allospecific T cell lines were not affected
by any of the three mutations. Representative results for
one line from each group are shown in Fig. 6, A and B.
When compared with the results for the Tax/HLA-A2–
specific T cell lines (201/201 lines affected by at least one
of the three mutations), the results clearly demonstrated
that TCRs that are specific for a peptide other than Tax
that is presented by HLA-A2 or recognize HLA-A2 as an
alloantigen do not focus on the same part of the interface
with the HLA-A2 molecule that is the focus of Tax-spe-
cific TCRs.
Effects of R65A, K66A, and A69G Mutations on Peptide
Binding and Presentation by HLA-A2. Do the R65A,
K66A, or A69G mutations affect binding and presentation
of the Tax peptide by the HLA-A2 molecule? As demon-
strated above, we readily found T cell lines that were unaf-
fected by these mutations, indicating that none of them im-
pair binding or presentation significantly enough to affect T
cell activation. Nevertheless, small decreases in peptide af-
finity not obvious in the cellular assays could influence the
Biacore binding measurements by decreasing the concen-
tration of active (i.e., peptide-bound) protein. This ques-
tion is particularly important for the R65A and K66A mu-
tants which show reduced TCR association rates (Table II).
To assay more directly for effects on peptide binding, we
performed circular dichroism temperature melting experi-
ments with the wild-type, R65A, K66A, and A69G Tax/
HLA-A2 molecules. Due to linkage between peptide bind-
ing and folding of the class I heavy chain, the apparent Tm
Table II. Kinetics and Affinities for HLA-A2/Tax Ligands Binding to A6 TCR at 258C
HLA-A2
sequence kon (M21s21) koff (s21) t1/2 (s)* koff/kon (mM) KD,eq (mM)
nG8
(kcal/mol)‡
Wild-type§ 1.1 6 0.1 3 105 0.093 6 0.002 7.5 6 0.2 0.82 6 0.08 0.91 6 0.09 8.24
R65A 829 6 193 0.079 6 0.002 8.8 6 0.2 96 6 22 84 6 32 5.56
K66A 3.2 6 0.3 3 103 0.050 6 0.002 13.9 6 0.6 15.6 6 1.2 18.7 6 7.5 6.45
A69G 5.5 6 0.3 3 104 0.682 6 0.026 1.02 6 0.04 12.4 6 0.9 9.6 6 0.4 6.84
T163A 6.0 6 0.2 3 104 0.168 6 0.009 4.13 6 0.22 2.8 6 0.2 3.1 6 0.2 7.51
E166A 4.6 6 0.5 3 104 0.197 6 0.008 3.51 6 0.14 4.3 6 0.2 4.0 6 0.2 7.36
W167A 1.2 6 0.1 3 105 0.572 6 0.023 1.21 6 0.05 4.8 6 0.4 6.9 6 0.4 7.04
*t1/2 5 0.693/koff.
‡nG8 5 2RTln KD, steady-state equilibrium values.
§From reference 5.
Figure 5. Recognition of Tax/HLA-A2 transfectants by B7-TCR
clone 10B7 as measured by cytotoxicity. E/T 5 2.5:1.557 Baker et al.
of the peptide/MHC is well correlated with peptide bind-
ing affinity (30). The results of these experiments are
shown in Fig. 7. As expected, none of the mutations signif-
icantly destabilize the molecule. Wild-type Tax/HLA-A2
was found to melt at 65.3 6 0.38C, identical to the value
previously measured in this laboratory (31). Surprisingly,
the R65A mutant had a Tm slightly higher than wild-type
(68.3 6 0.68C). The K66A mutant was slightly destabilized
relative to wild-type (Tm of 63.0 6 0.38C), suggesting
slightly weaker peptide binding. In other systems, a reduc-
tion in Tm of 2.3 degrees is correlated with an z1 order of
magnitude reduction in peptide binding affinity (30). Thus,
we cannot rule out the possibility that the slow TCR asso-
ciation rate for K66A is influenced somewhat by weaker
peptide binding. The A69G mutant is also slightly destabi-
lized (Tm of 64.1 6 0.78C), yet the effects of this mutation
on the TCR binding rate are modest (Table II).
Discussion
The Functional and Energetic Footprint of the A6 TCR on
Tax/HLA-A2. Wells and colleagues (35–37) have dem-
onstrated by alanine-scanning mutagenesis that dominant
contributions to binding energy within protein–protein in-
terfaces tend to cluster in localized regions providing an en-
ergetic footprint that is much smaller than the physical
footprint of an interaction. In this study, we have per-
formed a similar analysis within the interface between the
human class I MHC molecule HLA-A2 complexed with
the Tax peptide from the virus HTLV-1 and the human
TCR-a/b A6. Initially we examined the functional con-
tributions of the HLA-A2 amino acids contacted by the A6
TCR to T cell receptor signaling. For 12 out of 15 contact
residues, substitution with alanine (or glycine) had no sig-
nificant effect on TCR activity. The only substitutions that
did have an effect were R65A, K66A, and, to a lesser ex-
Table III. Summary of Anti-Tax CTL Recognition of R65A, 
K66A, and A69G
Negatively affected by:*
Patient
No. Tax-specific
CTL lines R65A K66A A69G
Mu 1 111
3 211
1 112
1 212
8 11 N.T.
2 21 N.T.
Total 16
Sa 42 111
8 211
3 212
7 112
1 221
Total 61
LB 68 N.T. 1 N.T.
JH 3 221
1 211
2 212
Total 6
DL 29 111
15 212
6 211
Total 50
Total 201
N.T., not tested.
*Negative effects of mutant HLA-A2 molecules are scored as “2” if
they produced a ,10-fold reduction in the amount of Tax peptide re-
quired to produce 50% of maximum lysis relative to wild-type HLA-
A2, and “1” if they produced a .10-fold reduction in activity.
Figure 6. Recognition of HLA-A2 molecules by T cells specific for in-
fluenza M1 peptide M1 58–66 and HLA-A2 allospecific T cells. (A) Rec-
ognition of M1 peptide-pulsed antigen-presenting cells was assayed by
lysis of the M1 peptide-specific CTL line 1E8 at E/T 5 5:1. (B) Recog-
nition of unpulsed antigen-presenting cells by the HLA-A2 allospecific T
cell line 1C1 at the indicated E/T ratios.558 Footprint on HLA-A2 for Tax Peptide/HLA-A2 TCR Recognition
tent, A69G. These three amino acids lie on the central por-
tion of the a1 helix and form contacts mainly with the
CDR3a loop of the A6 TCR (2). Thus, of the HLA-A2
amino acid side chains contacted by the TCR, this region
appears to represent an important “footprint” for A6 TCR
activity. The contributions from contacts to seven HLA-
A2 main chain atoms (involving positions 68, 69, 149, and
150, including hydrogen bonds made with the carbonyl
oxygen atoms of A149 and A150) could not be assayed.
Solution binding measurements showed that the three
HLA-A2 mutations affecting activity (R65A, K66A, and
A69G) also reduce A6 TCR binding affinity. In contrast,
measurements for three representative mutations that
showed no functional effect (T163A, E166A, and W167A)
demonstrated relatively minor effects on TCR binding af-
finity. These results were not unexpected, as previous stud-
ies have shown that reductions in TCR binding affinity re-
sulting from peptide alterations are often associated with
losses or decreases in TCR activity (for example, references
5, 38, and 39). The loss in affinity for A69G, which results
in weak TCR signaling, is intermediate between the affin-
ity loss for the two mutations which virtually abolish sig-
naling altogether (R65A and K66A) and those that show
no functional effect.
Each of the six HLA-A2 mutations assayed in the bind-
ing experiments resulted in weaker binding affinity (Table
II). Thus, binding energy appears to be distributed some-
what throughout the interface. Yet only the substitutions at
positions 65, 66, and 69 reduced affinity (or altered binding
kinetics) beyond a “threshold” required for full activity.
The nnG8 between the weak agonist A69G and full ago-
nist W167A mutants is ,1 kcal/mol, and the difference in
the half-lives is ,1 s (Table II). This illustrates the narrow
“window” of physical parameters (measured with soluble
molecules at 258C) that are generally correlated with T cell
function (for example, reference 40).
Of the MHC residues contacted by the TCR, Arg65 is
one of the few whose side chain is extended fully towards
the TCR. The guanidinium group of Arg65 forms a hy-
drogen bond with the hydroxyl group of Thr98 of the A6
TCR a-chain as well as a salt bridge with the carboxylate
of Asp99 (2). Complementary electrostatic interactions
across protein interfaces can increase association rates
through acceleration of diffusion and electrostatic orienta-
tion (41). The interactions with the A6 TCR made by
Arg65 may serve such a role, as substitution of Arg65 with
alanine reduces the apparent A6 TCR binding rate. How-
ever, the z133-fold reduction is substantial, larger than
what is typically observed with electrostatic rate enhance-
ments (for example, reference 42) and there may be other
factors contributing to the decrease (see below). Weaker
peptide binding is not likely to contribute to this slow rate,
as in addition to finding T cell lines unaffected by this mu-
tation (Table III), the R65A molecule has an apparent Tm
higher than that of wild-type (Fig. 7).
The dissociation rates (and thus half-lives) for wild-type
Tax/HLA-A2 and the R65A mutant are very similar (0.079
s21 for wild-type Tax/HLA-A2 and 0.093 s21 for R65A).
The A6 TCR/Tax/HLA-A2 structure does not provide an
indication why these values are so similar. Although it is
conceptually useful to cast the decrease in association rate as
an increase in the height of the transition state barrier to
binding (43) this does not provide insight into why the dis-
sociation rates are so similar. Apparently, once the complex
has formed, the strength of the intermolecular interactions
made with the A6 TCR by wild-type HLA-A2 and the
R65A mutant are similar. Structural reorganizations occur-
ring within the interface may result in new interactions that
make up for those lost by the R65A mutation. Such reor-
ganizations, if occurring, could also contribute to the
slower binding rate, as could any increase in flexibility re-
sulting from the mutation. Modeling or a crystallographic
Figure 7. Temperature stability of the wild-
type, R65A, K66A, and A69G HLA-A2 molecules
with the Tax peptide as measured by CD spectros-
copy at 218 nm. The apparent Tm, measured by
the inflection point of the fitted curve, is indicated
on each plot. Values on the y-axis indicate normal-
ized CD signal.559 Baker et al.
structure of the complex with the R65A mutant could pro-
vide insight into the molecular details underlying the re-
ductions in both association and dissociation rates.
In the TCR/peptide/MHC structure with the Tax/
HLA-A2–specific TCR-a/b B7, Arg65 also forms a hy-
drogen bond and a salt bridge with the B7 TCR a-chain
(4). As with the A6 TCR, the R65A substitution signifi-
cantly reduces cytotoxic activity with B7 TCR-bearing T
cells. This finding suggests that Arg65 acts in a similar role
for both the A6 and B7 TCRs. However, the contribution
of Arg65 cannot be as significant with other Tax/HLA-
A2–specific TCRs, as out of an additional 133 T cell lines
examined for negative effects with R65A, 45 were not ad-
versely affected. These other TCRs may not have comple-
mentary amino acids capable of forming hydrogen bonds or
salt bridges with Arg65 in the CDR3a loop and may com-
pensate for the loss of this interaction through other con-
tacts elsewhere in the interface.
The b-carbon of Ala69 forms a single hydrophobic con-
tact with the side chain of Trp101 of the A6 TCR a-chain.
Replacement of Ala69 with glycine significantly increases
the TCR dissociation rate, resulting in a TCR/peptide/
MHC half-life of 1.0 s (Table II; wild-type value is 7.5 s).
The increase in koff contributes to a weakening of the TCR
binding affinity by approximately one order of magnitude.
Although removal of the single hydrophobic contact made
by Ala69 likely contributes to the affinity loss, the effect of
replacing an alanine with the conformationally less re-
stricted glycine on the local structure of the MHC a1 helix
may also have an effect. However, the A69G substitution
did not have an adverse effect on activity with the B7
TCR, with which it makes a similar hydrophobic contact,
nor did it have an effect on 29 out of 123 additional T cell
lines screened.
As opposed to Arg65 and Ala69, the side chain of Lys66
does not protrude from the MHC; rather it lies parallel to
the peptide binding groove and helps bury the peptide an-
chor residue Leu2 (the g-carbon of the Lys66 side chain
also forms hydrophobic contacts with the b- and g-carbons
of Asp99 of the A6 TCR a-chain). As such, Lys66 does
not form any direct electrostatic interactions with the A6
TCR. Nevertheless, it still adds to the net charge of the
HLA-A2 TCR binding site and may contribute to electro-
static acceleration of the binding rate. Consistent with this
hypothesis, the K66A substitution reduces the apparent A6
TCR association rate by 34-fold. Again though, the reduc-
tion is large and there may be other factors contributing to
the rate decrease (see above). Circular dichroism melting
experiments indicate that the K66A mutant melts at a
slightly diminished Tm compared with wild-type (Fig. 7),
consistent with a reduction in peptide binding affinity. This
may contribute somewhat to the apparent decrease in
TCR association rate, yet the fact that we were able to find
T cell lines unaffected by the K66A mutation (Table III) as
well as purify normal quantities of the molecule indicates
that the effect on peptide binding is not substantial.
The TCR binding kinetics for K66A indicates that the
half-life of the TCR/peptide/MHC complex with the
K66A mutant is z14 s, or almost twice as long as wild-
type. As with the R65A mutant, the structure with wild-
type HLA-A2 does not provide insight into the reason for
this long half-life. In this case, once the complex is formed
the intermolecular interactions are stronger than in the
wild-type complex. Again, modeling or crystallographic
studies of the mutant complex would be insightful.
A Poor Correlation of Activity with TCR/Peptide/MHC
Half-Life. In many studies, the half-life of the TCR/pep-
tide/MHC complex is well correlated with activity (39).
Nevertheless, despite its long half-life (z14 s), the K66A
mutant is almost completely inactive. Likewise, the R65A
mutant, which has a TCR/peptide/MHC half-life similar
to wild-type (8.8 vs. 7.5 s; Table II), is inactive. As dis-
cussed, both mutants bind the A6 TCR slower than wild-
type HLA-A2. It is possible that the loss of function ob-
served with these two mutants is due to slow binding rates.
If more than one TCR must be engaged within a given
time interval for T cell activation to proceed, then the rates
at which TCR/peptide/MHC complexes form could in-
fluence in the quality or quantity of TCR signaling. A di-
rect correlation with affinity is ruled out, as the K66A mu-
tant binds with an affinity only z15–20-fold weaker than
wild-type, close to the value of A69G (partially active) and
in the range of peptide substitutions which are still partial
agonists. These two mutants add to a growing list of ligands
whose TCR dissociation rates do not correlate with activ-
ity (for example, references 38 and 44). Apparently, there
are factors other than the half-life of the TCR/peptide/
MHC complex that can affect T cell function.
Generality of the Footprint and the Role of the Peptide in Di-
recting TCR Focus. The 65/66/69 region is important for
recognition of Tax/HLA-A2 in general, as 201/201 Tax/
HLA-A2–specific cell lines were affected by at least one of
these substitutions (Table III). However, the fact that not
every cell line was equally affected by all three mutations as
well as the different response of the A6 and B7 TCRs to-
wards the A69G mutation indicates some Tax/HLA-A2–
specific TCRs can better accommodate substitutions in this
region. Similar patterns have been observed before: in their
mutational analysis, Ono et al. found that different TCRs
specific for VSV-based peptides presented by the mouse
class I MHC H-2Kb had slightly altered patterns of reactiv-
ity towards a panel of MHC mutations, although, as we
have observed, certain clusters tended to dominate (45).
In studying the effects of substitutions in the Tax peptide
upon recognition by the A6 TCR, Hausmann et al. ob-
served that substitution by alanine for three out of seven
nonanchor residues abolished cytotoxic activity (46). Fur-
thermore, alanine substitutions in other positions resulted
in an intermediate loss of activity similar to what we have
observed here with the A69G mutation. When compared
with our observation that alanine substitutions for only 2
out of 15 HLA-A2 residues contacted by the A6 TCR
abolish activity as well as the apparent generality of this
footprint, this implies that the Tax peptide plays a signifi-
cant role in influencing the TCR “focus”. Finding similar
results in a mouse class II MHC system, Ehrich et al. (47)560 Footprint on HLA-A2 for Tax Peptide/HLA-A2 TCR Recognition
concluded that the TCR-peptide/MHC interaction was
“dominated” by the peptide.
Studying the mouse 2C TCR binding to the QL9 pep-
tide presented by the class I MHC H2-Ld, Kranz and col-
leagues estimated that 37% of the binding energy results
from recognition of peptide, whereas 63% results from rec-
ognition of the MHC (48, 49). Similar results were ob-
tained for 2C TCR recognition of the SIYR peptide pre-
sented by H2-Kb (50). In both cases, these authors also
found the largest contributions stem from CDR loops 1
and 2. However, unlike here, in which we mutated MHC
positions contacted by the TCR, the results in the 2C sys-
tem stem from mutational analysis of the T cell receptor.
Furthermore, contact residues were predicted from molec-
ular models based on the structure of the 2C TCR com-
plexed with H-2Kb presenting the dEV8 peptide (3, 48).
Nevertheless, the results in the 2C system appear to contra-
dict ours, which imply a larger role for the peptide and by
extension, the CDR3 loops which generally form most
TCR-peptide contacts. As Kranz and colleagues suggested
(49, 50), this may reflect differences in CDR3 loop length
between the 2C and A6 TCRs, the latter of which are
longer. This may be one mechanism by which the peptide
influences TCR focus, as recognition of a given peptide
may require common TCR features (such as CDR3 loop
length and flexibility). Peptide conformation may require
subtle shifts in the geometry of the bound TCR, such that
smaller loops are unable to contact peptide/MHC. For ex-
ample, the Vb CDR1 and CDR2 loops of the A6 TCR do
not contact Tax/HLA-A2, whereas all Vb and Va loops
contact ligand in the structure of the 2C TCR complexed
with two different peptides presented by H-2Kb (3, 6).
Recognition of Tax/HLA-A2 also requires a conforma-
tional change in the peptide (2, 4), which may contribute
to the apparently large contributions made by the peptide
and CDR3 loops as well as diminish the contributions
made through other positions. Based on these consider-
ations, different energetic footprints might well be ex-
pected with different TCR-peptide/MHC interactions.
The 65/66/69 region is not the exclusive location of the
functional footprint on HLA-A2, as TCRs that are specific
for other HLA-A2–presented peptides are in some cases
sensitive to other sets of residues. We readily found allore-
active T cell lines as well as T cell lines specific for the in-
fluenza M1 58–66 peptide that were unaffected by either of
the R65A, K66A, and A69G mutations (preliminary results
suggest that position 155 is important for recognition of
HLA-A2 with the M1 peptide). Similar results have been
observed in other systems; for example, Ono et al. (45) also
observed that changes in the peptide altered TCR reactiv-
ity towards a panel of MHC mutants. Thus, there is little
evidence that any class I MHC residues evolved to “hold”
or “direct” the TCR into position, as TCRs of different
peptide specificity do not appear to focus on the same re-
gion of the MHC.
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